Reducing and Controlling Metabolic Active Tumor Volume Prior to CAR T Cell Infusion Can Improve Survival Outcomes in Patients with Large B Cell Lymphoma

The authors assessed the influence of quantified metabolic active tumor volume (MATV) and MATV-dynamics, between pre-apheresis and pre-lymphodepleting chemotherapy MATV, on CAR T-cell outcomes and toxicities in patients with relapsed or refractory large B cell lymphoma.